BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

VIVUS, Inc. (VVUS), Orexigen Therapeutics, Inc. (OREX) Stock Climb Ahead on Highly Anticipated FDA Decision


7/17/2012 8:14:50 AM

Shares of Vivus Inc. (US:vvus) jumped 5% to $28.63 Monday in anticipation that the U.S. Food and Drug Administration will soon approve its diet drug Qnexa. The FDA is scheduled to issue a decision by the end of Tuesday. Also gaining were shares of Orexigen Therapeutics (US:orex), up 7%. Orexigen announced last week that a clinical trial requested by the FDA for approval of its diet-drug candidate Contrave was ahead of schedule. Orexigen hopes to now have early results available by the end of 2013, rather than June 2014.

Read at Market Watch
Read at BusinessWeek
Read at Seeking Alpha
Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES